Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 17.06 -13.88% -2.75
RUBY closed down 13.88 percent on Thursday, December 13, 2018, on 1.6 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical RUBY trend table...

Date Alert Name Type % Chg
Dec 13 Fell Below 50 DMA Bearish 0.00%
Dec 13 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Dec 13 Multiple of Ten Bearish Other 0.00%
Dec 13 Strong but Oversold Other 0.00%
Dec 13 Below Lower BB Weakness 0.00%
Dec 13 Lower Bollinger Band Touch Weakness 0.00%
Dec 13 Oversold Stochastic Weakness 0.00%
Dec 12 20 DMA Resistance Bearish -13.88%
Dec 12 Multiple of Ten Bearish Other -13.88%
Dec 12 Strong but Oversold Other -13.88%

Older signals for RUBY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Is RUBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.01
52 Week Low 14.5
Average Volume 131,222
200-Day Moving Average 0.0
50-Day Moving Average 18.5246
20-Day Moving Average 20.3325
10-Day Moving Average 20.367
Average True Range 1.8001
ADX 14.75
+DI 20.5622
-DI 27.7554
Chandelier Exit (Long, 3 ATRs ) 18.5797
Chandelier Exit (Short, 3 ATRs ) 19.9003
Upper Bollinger Band 23.2869
Lower Bollinger Band 17.3781
Percent B (%b) -0.05
BandWidth 29.060863
MACD Line 0.0968
MACD Signal Line 0.5337
MACD Histogram -0.4369
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.86
Resistance 3 (R3) 22.37 21.29 21.06
Resistance 2 (R2) 21.29 20.06 21.03 20.79
Resistance 1 (R1) 19.17 19.31 18.63 18.66 20.53
Pivot Point 18.09 18.09 17.82 17.83 18.09
Support 1 (S1) 15.97 16.86 15.43 15.46 13.59
Support 2 (S2) 14.89 16.11 14.63 13.33
Support 3 (S3) 12.77 14.89 13.06
Support 4 (S4) 12.26